Uncategorized
Novel pan-VEGF inhibitor shows promise for treating AMD
BOSTON — A novel VEGF-C/D inhibitor showed preliminary evidence of clinical activity in patients with neovascular age-related macular degeneration, according to a study presented here.“Current treatments target primarily VEGF-A; OPT-302 (Opthea) inhibits VEGF-C as well as VEGF-D,” Pravin U. Dugel, MD, said at the American Society of Retina Specialists meeting, where he gave phase 1/2a study results for the VEGF inhibitor.